13 search results for: jak inhibitors

Impact of Advanced Systemic Therapies on Disease Control in AD
expert video

Impact of Advanced Systemic Therapies on Disease Control in AD

Dermatology
Dr. Simpson discusses impact of advanced systemic therapies in AD, and the link between inhibition of type 2 inflammation and reduced IgE levels.
View more
Skin Dysbiosis in AD
expert video

Skin Dysbiosis in AD

Dermatology
Dr. Lisa Beck discusses how S. aureus colonization contributes to a disrupted skin microbiome, skin barrier dysfunction, disease flares and increased disease severity in AD, and how blocking IL-4 and IL-13 can reduce S. aureus colonization.
View more
Current Treatment Landscape and Emerging Therapies
expert video

Current Treatment Landscape and Emerging Therapies

Dermatology
Dr. Lawrence F. Eichenfield reviews the evolving therapeutic landscape for children with AD, considering clinically relevant data supporting the use of advanced systemic therapies. This video was recorded at the EADV 2023 annual meeting during the ‘New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management’ presentation.
View more
New Perspectives in Understanding Pathophysiology of Atopic Dermatitis in Children
expert video

New Perspectives in Understanding Pathophysiology of Atopic Dermatitis in Children

Dermatology
Dr. Stephan Weidinger describes the roles of IL-4 and IL-13 in skin barrier dysfunction, and the potential of early control of type 2 inflammation to modify disease course. This video was recorded at the EADV 2023 annual meeting during the ‘New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management’ presentation.
View more
The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health
expert video

The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health

Dermatology
Dr. Marlies de Graaf highlights the potential long-term consequences of AD in children.
View more
The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD
expert video

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

Dermatology
Dr. Stephan Weidinger describes the relationship between skin barrier dysfunction and increased risk of allergen sensitization in AD.
View more
New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management
expert video

New Horizons in Children With Atopic Dermatitis: Emerging Evidence in Disease Management

Dermatology
Review the evolving therapeutic landscape for children with AD, considering clinically relevant data supporting the use of advanced systemic therapies.
View more
EAACI 2023 | What is New in the Treatment of Children
expert video

EAACI 2023 | What is New in the Treatment of Children

Dermatology
Clinical trial and real-world data for targeted therapies for children with atopic dermatitis – Presentation from the ADVENT symposium at EAACI 2023.
View more
Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention? - Q&As
expert video

Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention? - Q&As

Dermatology
Clinical trial and real-world data for targeted therapies for children with atopic dermatitis– Presentation from the ADVENT symposium at EAACI 2023.
View more
Targeting Type 2 Inflammation in Children with AD​
expert video

Targeting Type 2 Inflammation in Children with AD​

Dermatology
The impact of type 2 inflammation in itch and barrier dysfunction in atopic dermatitis – Presentation from the ADVENT symposium at EAACI 2023.
View more
Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention?
expert video

Targeting Type 2 Inflammation in Children with Atopic Dermatitis: Opportunity for Early Intervention?

Dermatology
Presentations from the ADVENT symposium at the EAACI 2023 congress on targeting type 2 Inflammation in children with atopic dermatitis.
View more
The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 
expert video

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 

Dermatology
Multidimensional disease burden of atopic dermatitis in children from a real-world case study – Presentation from the ADVENT symposium at EAACI 2023.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: DenmarkChange country/region